Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis

Sponsor
University of Manitoba
Study ID
NCT00963703
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    Rituximab 1000 mg Intravenously day 1 and day 15

Study Details

The purpose of this study is to determine how well Rituximab works in early stages of disease and the effects it has on an inflamed joint and blood cells. This will allow the investigators to get a better understanding of how this treatment affects the inflamed joints of rheumatoid arthritis (RA) patients.

Key Dates

Start date
Dec 31, 2007
Status verified
Mar 2012
Primary completion
Mar 31, 2012
Completion
Mar 31, 2012

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Rituximab

Primary Outcome Measure

To define the synovial effects of rituximab treatment in TNFa naive patients with early rheumatoid arthritis [ Time Frame: Biopsies of inflamed joint at beginning and at week 8 of study ]

Related Studies